MS Australia is bringing together the nation’s top researchers to study the complex link between Epstein-Barr virus (EBV) and multiple sclerosis (MS) – with the potential to
revolutionise how we treat, prevent, and ultimately cure MS.
The EBV in MS National Collaborative Platform, launched last week at MS Australia’s inaugural Frontiers in MS Research Symposium at the University of Sydney, brings together researchers, resources, and diverse expertise in EBV and MS across Australia.
How will this help?
EBV is one of the most widespread viruses globally, with around 90 per cent of adults infected. It can cause glandular fever, but many people experience mild or no symptoms
and may never realise they carry it. But EBV infection increases the risk of developing MS, with virtually all people diagnosed with MS having a history of EBV. Investigating this link has become one of the most promising areas of MS research.
MS Australia’s Head of Research, Dr Julia Morahan said landmark discoveries in 2022 provided compelling evidence that EBV is necessary for the development of MS.
“The immune response to EBV might set the stage for immune attack on the brain and spinal
cord in MS,” Dr Morahan said.
She added that by consolidating research efforts, it is hoped to accelerate discoveries into
the role of EBV in MS.
“Together we are investigating innovative treatments and the development of vaccines, with the ultimate hope that this effort brings us closer to the goal of preventing MS,” she said.